Anti-AKT1 (phospho S473) antibody (ab18206)

Overview

• Product nameAnti-AKT1 (phospho S473) antibodySee all AKT1 primary antibodies ...
• Description
  Rabbit polyclonal to AKT1 (phospho S473)
• SpecificityThe immunogen was raised against Human AKT1 phosphorylated at serine 473, however due to the high degree of similarity between AKT1, AKT2 and AKT3 the antibody is also predicted to react with all these isoforms.
• Tested applicationsWB more details
• Species reactivity
  Reacts with: Mouse, African Green Monkey
  Predicted to work with: Rat, Cow, Human, Xenopus laevis
• Immunogen

  Synthetic peptide conjugated to KLH derived from within residues 450 to the C-terminus of Human AKT, phosphorylated at S473.

  Read Abcam's proprietary immunogen policy

  (Peptide available as ab18622.)

• Positive controlThis antibody gave a positive signal in NIH 3T3 treated with Vanadate and PDGF Whole Cell Lysate

Properties

• FormLiquid
• Storage instructionsStore at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
• Storage bufferPreservative: 0.02% Sodium Azide
  Constituents: 1% BSA, PBS, pH 7.4
• Concentration information loading...
• PurityImmunogen affinity purified
• Clonality Polyclonal
• IsotypeIgG
• Research Areas
  • Metabolism
  • Pathways and Processes
  • Metabolism processes
  • Apoptosis

  • Cancer
  • Signal transduction
  • Protein phosphorylation
  • Serine/threonine kinases
  • AKT

  • Signal Transduction
  • Protein Phosphorylation
  • Ser / Thr Kinases
  • PKB / AKT

  • Epigenetics and Nuclear Signaling
  • Cell cycle
  • Apoptosis
  • Nuclear

  • Neuroscience
  • Neurology process
  • Neural Signal Transduction

Applications

Target

• FunctionPlays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). General protein kinase capable of phosphorylating several known proteins. Phosphorylates TBC1D4. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). Plays a role in glucose transport by mediating insulin-induced translocation of the GLUT4 glucose transporter to the cell surface. Mediates the antiapoptotic effects of IGF-I. Mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. Promotes glycogen synthesis by mediating the insulin-induced activation of glycogen synthase. The activated form can suppress FoxO gene transcription and promote cell cycle progression. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly.
• Tissue specificityExpressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages.
• Involvement in diseaseDefects in AKT1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
  Defects in AKT1 are associated with colorectal cancer (CRC) [MIM:114500].
  Defects in AKT1 are associated with susceptibility to ovarian cancer [MIM:604370]; also called susceptibility to familial breast-ovarian cancer type 1 (BROVCA1).
• Sequence similaritiesBelongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. RAC subfamily.
  Contains 1 AGC-kinase C-terminal domain.
  Contains 1 PH domain.
  Contains 1 protein kinase domain.
• DomainBinding of the PH domain to the phosphatidylinositol 3-kinase alpha (PI(3)K) results in its targeting to the plasma membrane. The PH domain mediates interaction with TNK2 and Tyr-176 is also essential for this interaction.
  The AGC-kinase C-terminal mediates interaction with THEM4.
• Post-translational
  modificationsPhosphorylation on Thr-308, Ser-473 and Tyr-474 is required for full activity. Activated TNK2 phosphorylates it on Tyr-176 resulting in its binding to the anionic plasma membrane phospholipid PA. This phosphorylated form localizes to the cell membrane, where it is targeted by PDPK1 and PDPK2 for further phosphorylations on Thr-308 and Ser-473 leading to its activation. Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylation by PDPK1. Ser-473 phosphorylation is enhanced by interaction with AGAP2 isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focal cortical dysplasias with Taylor-type balloon cells.
  Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1 ubiquitination is critical for phosphorylation and activation. When ubiquitinated, it translocates to the plasma membrane, where it becomes phosphorylated. When fully phosphorylated and translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradation by the proteasome.
• Cellular localizationCytoplasm. Nucleus. Cell membrane. Nucleus after activation by integrin-linked protein kinase 1 (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. Phosphorylation on Tyr-176 by TNK2 results in its localization to the cell membrane where it is targeted for further phosphorylations on Thr-308 and Ser-473 leading to its activation and the activated form translocates to the nucleus.

Target information above from: UniProt accession P31749 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 280991 Cow
  • Entrez Gene: 207 Human
  • Entrez Gene: 11651 Mouse
  • Entrez Gene: 24185 Rat
  • Entrez Gene: 399170 Xenopus laevis
  • Omim: 164730 Human
  • SwissProt: Q01314 Cow
  • SwissProt: P31749 Human

  • SwissProt: P31750 Mouse
  • SwissProt: P47196 Rat
  • SwissProt: Q98TY9 Xenopus laevis
  • Unigene: 525622 Human
  • Unigene: 6645 Mouse
  • Unigene: 11422 Rat
  • Unigene: 738 Xenopus laevis

  see all

• Alternative names
  AKT 1 antibodyAKT 2 antibodyAKT 3 antibody

  AKT antibodyAKT1 antibodyAKT1_HUMAN antibodyAKT2 antibodyAKT3 antibodyC AKT antibodyC AKT antibodyCAKT antibodyDKFZP434N0250 antibodyMGC99656 antibodyMurine thymoma viral (v akt) homolog 2 antibodymurine thymoma viral (v akt) oncogene homolog 1 antibodyMurine thymoma viral (vakt) oncogene homolog 1 antibodyPKB Akt antibodyPKB Akt antibodyPKB alpha antibodyPKB antibodyPKB beta antibodyPKB-ALPHA antibodyPKBalpha antibodyPKBalpha antibodyPKBBETA antibodyPKBG antibodyPRKBA antibodyPRKBA antibodyPRKBB antibodyPRKBG antibodyProtein kinase Akt 2 antibodyProtein kinase Akt 3 antibodyProtein Kinase B Alpha antibodyProtein kinase B antibodyProtein kinase B beta antibodyProtein kinase B gamma antibodyProto-oncogene c-Akt antibodyRAC alpha antibodyRAC alpha serine/threonine protein kinase antibodyRAC antibodyRAC beta antibodyRAC beta serine/threonine protein kinase antibodyRAC gamma antibodyRAC gamma serine/threonine protein kinase antibodyRAC PK alpha antibodyRAC PK beta antibodyRAC PK gamma antibodyRac protein kinase alpha antibodyRac protein kinase beta antibodyRAC Serine/Threonine Protein Kinase antibodyRAC Serine/Threonine Protein Kinase antibodyRAC-alpha serine/threonine-protein kinase antibodyRAC-PK-alpha antibodySerine threonine protein kinase Akt 3 antibodySTK 2 antibodySTK2 antibodyV AKT Murine Thymoma Viral Oncogene Homolog 1 antibodyV AKT Murine Thymoma Viral Oncogene Homolog 1 antibodyv akt murine thymoma viral oncogene homolog 2 antibodyv akt murine thymoma viral oncogene homolog 3 antibodyvAKT Murine Thymoma Viral Oncogene Homolog 1 antibodyVAKT Murine Thymona Viral Oncogene 1 antibody

  see all

Anti-AKT1 (phospho S473) antibody images

• 

  Western blot - pan-AKT (phospho S473) antibody (ab18206)
  All lanes : Anti-AKT1 (phospho S473) antibody (ab18206) at 1 µg/ml
  
  Lane 1 : NIH 3T3 (Mouse embryonic fibroblast cell line) Whole Cell Lysate
  Lane 2 : NIH 3T3 treated with Vanadate and PDGF Whole Cell Lysate
  Lane 3 : NIH 3T3 (Mouse embryonic fibroblast cell line) Whole Cell Lysate with pan-AKT peptide - phospho S473 (ab18622) at 1 µg/ml
  Lane 4 : NIH 3T3 treated with Vanadate and PDGF Whole Cell Lysate with pan-AKT peptide - phospho S473 (ab18622) at 1 µg/ml
  Lane 5 : NIH 3T3 (Mouse embryonic fibroblast cell line) Whole Cell Lysate with AKT1 peptide - unmodified (ab24649) at 1 µg/ml
  Lane 6 : NIH 3T3 treated with Vanadate and PDGF Whole Cell Lysate with AKT1 peptide - unmodified (ab24649) at 1 µg/ml
  
  Lysates/proteins at 20 µg per lane.
  
  Secondary
  Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
  
  Performed under reducing conditions.
  
  Predicted band size : 57 kDa
  Observed band size : 57-60 kDa (why is the actual band size different from the predicted?)
  Additional bands at : 130 kDa,78 kDa. We are unsure as to the identity of these extra bands.
  
  Exposure time : 2 minutes